Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Online Information Landscape and Oxalate Content of Purportedly Antilithogenic Ingredients.

Journal of endourology·2025
Same author

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones.

The Journal of urology·2025
Same author

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026) Part I: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones.

The Journal of urology·2025
Same author

Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part III: Treatment of Patients With Kidney and/or Ureteral Stones and Future Directions.

The Journal of urology·2025
Same author

Evaluating the efficacy of the VAMS Mitra microsampler for whole blood trace element analysis.

Bioanalysis·2025
Same author

Microbiota and kidney disease: the road ahead.

Nature reviews. Nephrology·2025

Related Experiment Video

Updated: Jun 12, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

Do proton pump inhibitors decrease calcium absorption?

Karen E Hansen1, Andrea N Jones, Mary J Lindstrom

  • 1Department of Medicine, University of Wisconsin, Madison, WI, USA. keh@medicine.wisc.edu

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|June 26, 2010
PubMed
Summary
This summary is machine-generated.

Proton pump inhibitors (PPIs) do not appear to reduce calcium absorption in postmenopausal women, despite concerns about fracture risk. Further research is needed to understand how PPIs increase osteoporotic fracture risk.

More Related Videos

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry
10:24

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry

Published on: October 28, 2014

Related Experiment Videos

Last Updated: Jun 12, 2026

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3
07:26

Cell-based Calcium Assay for Medium to High Throughput Screening of TRP Channel Functions using FlexStation 3

Published on: August 17, 2011

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry
10:24

Cytosolic Calcium Measurements in Renal Epithelial Cells by Flow Cytometry

Published on: October 28, 2014

Area of Science:

  • Endocrinology
  • Gastroenterology
  • Nutritional Science

Background:

  • Proton pump inhibitors (PPIs) are linked to increased osteoporotic fracture risk.
  • This risk is hypothesized to stem from reduced fractional calcium absorption (FCA) due to PPI-induced hypochlorhydria.
  • Previous studies on PPIs' direct impact on FCA have yielded conflicting results.

Purpose of the Study:

  • To investigate the direct effect of PPI therapy on fractional calcium absorption (FCA) in postmenopausal women.
  • To determine if PPI-induced hypochlorhydria impacts calcium absorption.
  • To explore potential factors influencing changes in FCA during PPI use.

Main Methods:

  • Twenty-one postmenopausal women underwent three 24-hour inpatient fractional calcium absorption (FCA) studies using a dual stable isotope method.
  • Baseline FCA was measured across two separate visits.
  • A third FCA study was conducted after 30 days of daily omeprazole (40 mg/day) administration, with participants consuming identical meals replicating their dietary habits.

Main Results:

  • Mean FCA was 20% ± 10% at visit 1, 18% ± 10% at visit 2, and 23% ± 10% after 30 days of omeprazole (p = 0.07).
  • No significant decrease in FCA was observed following 30 days of continuous omeprazole use.
  • Age, gastric pH, serum omeprazole levels, adherence, and 25-hydroxyvitamin D levels did not correlate with changes in FCA. Only 1,25-dihydroxyvitamin D(3) levels at visit 2 were associated with FCA change (p = 0.049).

Conclusions:

  • Thirty days of continuous proton pump inhibitor (PPI) use, specifically omeprazole, did not decrease fractional calcium absorption (FCA) in postmenopausal women.
  • The findings suggest that PPI-associated hypochlorhydria may not be the primary mechanism reducing calcium absorption.
  • Further research is warranted to elucidate the mechanisms linking PPI use to an increased risk of osteoporotic fractures.